Sleep Disorders

Overview

Sleep disorders addressed by peptide therapy include insomnia, disrupted circadian rhythms, poor sleep architecture, and low slow-wave sleep (SWS). Peptides targeting the pineal-melatonin axis, delta sleep-inducing pathways, and GH secretagogue pathways (since the majority of GH is released during SWS) offer distinct and complementary mechanisms. Improving sleep architecture produces cascading benefits for recovery, cognition, metabolism, and longevity.

Recommended Peptides

Epitalon – restores melatonin production by rejuvenating pineal gland function; particularly useful in aging-related circadian disruption; also normalizes cortisol rhythms; nighttime dosing
DSIP – delta sleep-inducing peptide; endogenous peptide that promotes slow-wave and REM sleep; also has anxiolytic and antistress effects
CJC-1295 / Ipamorelin – GHRH/GHRP combination that amplifies the natural GH pulse during SWS; improves sleep quality and recovery; pre-sleep fasted dosing is critical
MK-677 – oral GH secretagogue (not a peptide, but often grouped with them); significantly increases SWS and GH output; convenient oral dosing but can cause fluid retention and insulin resistance at higher doses

Protocols

Related Conditions

Research Summary

DSIP (Delta Sleep-Inducing Peptide) produced both acute sleep promotion and delayed sleep quality improvements in a human clinical study (PMID-6895513). DSIP also modulates stress-related neuronal activation in limbic structures (PMID-22432135). Epitalon restores melatonin production in aged primates (3-fold increase in nocturnal peaks) (PMID-12096440).

#condition #neurological